Phase 1 Trial of a Therapeutic Anti–Yellow Fever Virus Human Antibody
Copyright © 2020 Massachusetts Medical Society. BACKGROUND Insufficient vaccine doses and the lack of therapeutic agents for yellow fever put global health at risk, should this virus emerge from sub-Saharan Africa and South America. METHODS In phase 1a of this clinical trial, we assessed the safety,...
Main Authors: | Low, Jenny G, Ng, Justin HJ, Ong, Eugenia Z, Kalimuddin, Shirin, Wijaya, Limin, Chan, Yvonne FZ, Ng, Dorothy HL, Tan, Hwee-Cheng, Baglody, Anjali, Chionh, Yok-Hian, Lee, Debbie CP, Budigi, Yadunanda, Sasisekharan, Ram, Ooi, Eng-Eong |
---|---|
Format: | Article |
Language: | English |
Published: |
Massachusetts Medical Society
2021
|
Online Access: | https://hdl.handle.net/1721.1/133594 |
Similar Items
-
Phase 1 Trial of a Therapeutic Anti–Yellow Fever Virus Human Antibody
by: Low, Jenny G, et al.
Published: (2022) -
Yellow fever – what it means for Singapore
by: Lim, Poh Lian, et al.
Published: (2019) -
New diagnostic tools for yellow fever
by: Leong, Wei Yee
Published: (2020) -
Responding to the threat of urban yellow fever outbreaks
by: Wilder-Smith, Annelies, et al.
Published: (2017) -
Yellow fever cases in Asia: primed for an epidemic
by: Lim, Poh Lian, et al.
Published: (2018)